Skip to menu Skip to content Skip to footer

2018

Journal Article

Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials

Zimmermann, Heiner, Babel, Nina, Dierickx, Daan, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M., Dreyling, Martin H., Dührsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Hüttmann, Andreas, Tousseyn, Thomas, Bachy, Emmanuel, Hauser, Ingeborg A., Tarella, Corrado, Van Den Neste, Eric, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno, Choquet, Sylvain and Trappe, Ralf U. (2018). Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials. Transplantation, 102 (11), 1914-1923. doi: 10.1097/TP.0000000000002269

Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: a retrospective analysis based on the prospective, international, multicenter PTLD-1 trials

2018

Journal Article

Pomalidomide – author reply

Scott, Ashleigh P. and Mollee, Peter (2018). Pomalidomide – author reply. Leukemia and Lymphoma, 60 (4), 1-1. doi: 10.1080/10428194.2018.1516884

Pomalidomide – author reply

2018

Journal Article

Relative survival of patients with lymphoma in Queensland according to histological subtype

Wright, Fraser, Hapgood, Greg, Loganathan, Aravi, Dunn, Nathan, Philpot, Shoni, Moore, Julie and Mollee, Peter (2018). Relative survival of patients with lymphoma in Queensland according to histological subtype. Medical Journal of Australia, 209 (4), 166-172. doi: 10.5694/mja17.00937

Relative survival of patients with lymphoma in Queensland according to histological subtype

2018

Journal Article

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Quach, Hang, Benson, Simon, Haysom, Helen, Wilkes, Anne-Marie, Zacher, Nicole, Cole-Sinclair, Merrole, Miles Prince, Henry, Mollee, Peter, Spencer, Andrew, Joy Ho, Phoebe, Harrison, Simon J, Lee, Cindy, Augustson, Bradley and Daly, James (2018). Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Internal Medicine Journal, 48 (2), 210-220. doi: 10.1111/imj.13707

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

2017

Journal Article

A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins

Tate, Jillian R., Keren, David F. and Mollee, Peter (2017). A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins. Clinical Biochemistry, 51, 4-9. doi: 10.1016/j.clinbiochem.2017.11.009

A global call to arms for clinical laboratories - Harmonised quantification and reporting of monoclonal proteins

2017

Journal Article

The treatment of paraprotein-related kidney disease

Hutchison, Colin A., Xiong, Fei and Mollee, Peter (2017). The treatment of paraprotein-related kidney disease. Current Opinion in Nephrology and Hypertension, 26 (6), 477-483. doi: 10.1097/MNH.0000000000000369

The treatment of paraprotein-related kidney disease

2017

Journal Article

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

Scott, Ashleigh, Weber, Nicholas, Tiley, Campbell, Taylor, Kerry, Taper, John, Harrison, Simon, Chan, Kah-Lok, Stark, Richard, Lee, Cindy, Morris, Kirk, Ho, P. Joy, Dodds, Anthony, Ramanathan, Sundra, Ramakrishna, Raj, Watson, Anne-Marie, Auguston, Bradley, Kwok, Fiona, Quach, Hang, Warburton, Pauline, Rowlings, Philip and Mollee, Peter (2017). ‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 59 (6), 1514-1516. doi: 10.1080/10428194.2017.1387911

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

2017

Journal Article

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Lee, Oi Lin, Horvath, Noemi, Lee, Cindy, Joshua, Doug, Ho, Joy, Szer, Jeff, Quach, Hang, Spencer, Andrew, Harrison, Simon, Mollee, Peter, Roberts, Andrew W., Talaulikar, Dipti, Brown, Ross, Augustson, Bradley, Ling, Silvia, Jaksic, Wilfrid, Gibson, John, Kalff, Anna, Johnston, Anna, Kalro, Akash, Ward, Chris, Prince, H. Miles and Zannettino, Andrew (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 47 (8), 938-951. doi: 10.1111/imj.13502

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

2017

Journal Article

The duality of macrophage function in Chronic Lymphocytic Leukaemia

Chen, Y. C. E., Mapp, S., Blumenthal, A., Burgess, M. L., Mazzieri, R., Mattarollo, S., Mollee, P., Gill, D. and Saunders, N. A. (2017). The duality of macrophage function in Chronic Lymphocytic Leukaemia. Biochimica et Biophysica Acta (BBA) Reviews on Cancer, 1868 (1), 176-182. doi: 10.1016/j.bbcan.2017.03.006

The duality of macrophage function in Chronic Lymphocytic Leukaemia

2017

Journal Article

Monitoring of light chain myeloma - time for a change

Mollee, Peter and Tate, Jill (2017). Monitoring of light chain myeloma - time for a change. British Journal of Haematology, 178 (2), 177-178. doi: 10.1111/bjh.14752

Monitoring of light chain myeloma - time for a change

2017

Journal Article

Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting

Sharkey, Megan M., McKavanagh, Daniel, Walpole, Euan, Mollee, Peter and Hollingworth, Samantha A. (2017). Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. International Journal of Clinical Pharmacy, 39 (4), 836-843. doi: 10.1007/s11096-017-0480-0

Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting

2017

Journal Article

Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial

Rickard, Claire M., Marsh, Nicole M., Webster, Joan, Gavin, Nicole C., Chan, Raymond J., McCarthy, Alexandra L., Mollee, Peter, Ullman, Amanda J., Kleidon, Tricia, Chopra, Vineet, Zhang, Li, McGrail, Matthew R., Larsen, Emily, Abu Choudhury, Md, Keogh, Samantha, Alexandrou, Evan, McMillan, David J., Mervin, Merehau Cindy, Paterson, David L., Cooke, Marie, Ray-Barruel, Gillian, Castillo, Maria Isabel, Hallahan, Andrew, Corley, Amanda and Playford, E. Geoffrey (2017). Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. BMJ Open, 7 (6) e015291, e015291. doi: 10.1136/bmjopen-2016-015291

Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial

2017

Journal Article

Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?

Hill, Michelle M. and Mollee, Peter N. (2017). Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?. Expert Review of Proteomics, 14 (7), 565-566. doi: 10.1080/14789450.2017.1322905

Mass spectrometry analysis for amyloidosis typing - is the future bright for its clinical implementation?

2017

Journal Article

Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia

Fleming, Shaun, Ong, Doen Ming, Jackson, Kathryn, Avery, Sharon, Mollee, Peter, Marlton, Paula, Kennedy, Glen and Wei, Andrew H (2017). Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. British Journal of Haematology, 177 (2), 328-330. doi: 10.1111/bjh.14063

Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia

2017

Journal Article

Malabsorption secondary to gout-induced amyloidosis

Azzam, Ali, Balasubramaniam, Renuka, Safa, Shahram, McIvor, Carolyn and Mollee, Peter (2017). Malabsorption secondary to gout-induced amyloidosis. ACG Case Reports Journal, 4 (1), e32. doi: 10.14309/crj.2017.32

Malabsorption secondary to gout-induced amyloidosis

2017

Journal Article

Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial

Trappe, Ralf U., Dierickx, Daan, Zimmermann, Heiner, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M., Dreyling, Martin H., Duhrsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Huttmann, Andreas, Tousseyn, Thomas, Salles, Gilles, Kliem, Volker, Hauser, Ingeborg A., Tarella, Corrado, Neste, Eric Van Den, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno and Choquet, Sylvain (2017). Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial. Journal of Clinical Oncology, 35 (5), 536-543. doi: 10.1200/JCO.2016.69.3564

Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial

2017

Journal Article

Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome : MGRS triggering aHUS

Mahmood, Usman, Isbel, Nicole, Mollee, Peter, Mallett, Andrew, Govindarajulu, Sridevi and Francis, Ross (2017). Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome : MGRS triggering aHUS. Nephrology, 22 (S1), 15-17. doi: 10.1111/nep.12934

Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome : MGRS triggering aHUS

2017

Journal Article

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, Dipti, Tam, Constantine S., Joshua, Douglas, Ho, Joy Phoebe, Szer, Jeff, Quach, Hang, Spencer, Andrew, Harrison, Simon, Mollee, Peter, Roberts, Andrew W., Horvath, Noemi, Lee, Cindy, Zannettino, Andrew, Brown, Ross, Augustson, Bradley, Jaksic, Wilfrid, Gibson, John, Kalff, Anna, Johnston, Anna, Trotman, Judith, Kalro, Akash, Grigoriadis, George, Ward, Chris and Prince, H. Miles (2017). Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47 (1), 35-49. doi: 10.1111/imj.13311

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

2016

Journal Article

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

Bergin, Krystal, Moore, Elizabeth, McQuilten, Zoe, Wood, Erica, Augustson, Bradley, Blacklock, Hilary, Ho, Joy, Horvath, Noemi, King, Tracy, McNeil, John, Mollee, Peter, Quach, Hang, Reid, Christopher M., Rosengarten, Brian, Walker, Patricia and Spencer, Andrew (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. Bmc Medical Research Methodology, 16 (1) 151, 151. doi: 10.1186/s12874-016-0250-z

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

2016

Journal Article

The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience

Moore, Peter T., Burrage, Matthew K., Mackenzie, Emily, Law, W. Philip, Korczyk, Dariusz and Mollee, Peter (2016). The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience. Heart, Lung and Circulation, 26 (11), 1183-1190. doi: 10.1016/j.hlc.2016.12.017

The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience